Literature DB >> 18357616

Fragile X-associated primary ovarian insufficiency: evidence for additional genetic contributions to severity.

Jessica Ezzell Hunter1, Michael P Epstein, Stuart W Tinker, Krista H Charen, Stephanie L Sherman.   

Abstract

The fragile X mental retardation gene (FMR1) contains a CGG repeat sequence in its 5' untranslated region that can become unstable and expand in length from generation to generation. Alleles with expanded repeats in the range of approximately 55-199, termed premutation alleles, are associated with an increased risk for fragile-X-associated primary ovarian insufficiency (FXPOI). However, not all women who carry the premutation develop FXPOI. To determine if additional genes could explain variability in onset and severity, we used a random-effects Cox proportional hazards model to analyze age at menopause on 680 women from 225 families who have a history of fragile X syndrome and 321 women from 219 families from the general population. We tested for the presence of a residual additive genetic effect after adjustment for FMR1 repeat length, race, smoking, body mass index, and method of ascertainment. Results showed significant familial aggregation of age at menopause with an estimated additive genetic variance of 0.55-0.96 depending on the parameterization of FMR1 repeat size and definition of age at menopause (P-values ranging between 0.0002 and 0.0027). This is the first study to analyze familial aggregation of FXPOI. This result is important for proper counseling of women who carry FMR1 premutation alleles and for guidance of future studies to identify additional genes that influence ovarian insufficiency. (c) 2008 Wiley-Liss, Inc.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18357616      PMCID: PMC2881575          DOI: 10.1002/gepi.20329

Source DB:  PubMed          Journal:  Genet Epidemiol        ISSN: 0741-0395            Impact factor:   2.135


  32 in total

1.  Elevated levels of FMR1 mRNA in carrier males: a new mechanism of involvement in the fragile-X syndrome.

Authors:  F Tassone; R J Hagerman; A K Taylor; L W Gane; T E Godfrey; P J Hagerman
Journal:  Am J Hum Genet       Date:  2000-01       Impact factor: 11.025

2.  Random-effects Cox proportional hazards model: general variance components methods for time-to-event data.

Authors:  V Shane Pankratz; Mariza de Andrade; Terry M Therneau
Journal:  Genet Epidemiol       Date:  2005-02       Impact factor: 2.135

3.  Heritability of age at natural menopause in the Framingham Heart Study.

Authors:  Joanne M Murabito; Qiong Yang; Caroline Fox; Peter W F Wilson; L Adrienne Cupples
Journal:  J Clin Endocrinol Metab       Date:  2005-03-15       Impact factor: 5.958

4.  Modeling age at menopause.

Authors:  Jacqueline Vink; Dorret Boomsma
Journal:  Fertil Steril       Date:  2005-04       Impact factor: 7.329

5.  Clinical involvement and protein expression in individuals with the FMR1 premutation.

Authors:  F Tassone; R J Hagerman; A K Taylor; J B Mills; S W Harris; L W Gane; P J Hagerman
Journal:  Am J Med Genet       Date:  2000-03-13

6.  Nonlinear association between CGG repeat number and age of menopause in FMR1 premutation carriers.

Authors:  Sarah Ennis; Daniel Ward; Anna Murray
Journal:  Eur J Hum Genet       Date:  2006-02       Impact factor: 4.246

7.  Heritability of menopausal age in mothers and daughters.

Authors:  Kristel M van Asselt; Helen S Kok; Peter L Pearson; Judith S Dubas; Petra H M Peeters; Egbert R Te Velde; Paulus A H van Noord
Journal:  Fertil Steril       Date:  2004-11       Impact factor: 7.329

Review 8.  Primary ovarian insufficiency: a more accurate term for premature ovarian failure.

Authors:  Corrine K Welt
Journal:  Clin Endocrinol (Oxf)       Date:  2007-10-29       Impact factor: 3.478

9.  Examination of reproductive aging milestones among women who carry the FMR1 premutation.

Authors:  E G Allen; A K Sullivan; M Marcus; C Small; C Dominguez; M P Epstein; K Charen; W He; K C Taylor; S L Sherman
Journal:  Hum Reprod       Date:  2007-06-22       Impact factor: 6.918

10.  Fragile X syndrome: diagnostic and carrier testing.

Authors:  Stephanie Sherman; Beth A Pletcher; Deborah A Driscoll
Journal:  Genet Med       Date:  2005-10       Impact factor: 8.822

View more
  14 in total

Review 1.  Advances in the Understanding of the Gabaergic Neurobiology of FMR1 Expanded Alleles Leading to Targeted Treatments for Fragile X Spectrum Disorder.

Authors:  Reymundo Lozano; Veronica Martinez-Cerdeno; Randi J Hagerman
Journal:  Curr Pharm Des       Date:  2015       Impact factor: 3.116

Review 2.  Can we make assumptions about the psychosocial impact of living as a carrier, based on studies assessing the effects of carrier testing?

Authors:  Celine Lewis; Heather Skirton; Ray Jones
Journal:  J Genet Couns       Date:  2010-09-29       Impact factor: 2.537

3.  The Flat Earth Society: a rose by any other name?

Authors:  Lawrence M Nelson
Journal:  Hum Reprod       Date:  2013-12-16       Impact factor: 6.918

4.  A Variance-Component Framework for Pedigree Analysis of Continuous and Categorical Outcomes.

Authors:  Michael P Epstein; Jessica E Hunter; Emily G Allen; Stephanie L Sherman; Xihong Lin; Michael Boehnke
Journal:  Stat Biosci       Date:  2009-11

Review 5.  Unstable mutations in the FMR1 gene and the phenotypes.

Authors:  Danuta Loesch; Randi Hagerman
Journal:  Adv Exp Med Biol       Date:  2012       Impact factor: 2.622

6.  Relationships between age and epi-genotype of the FMR1 exon 1/intron 1 boundary are consistent with non-random X-chromosome inactivation in FM individuals, with the selection for the unmethylated state being most significant between birth and puberty.

Authors:  David E Godler; Yoshimi Inaba; Elva Z Shi; Cindy Skinner; Quang M Bui; David Francis; David J Amor; John L Hopper; Danuta Z Loesch; Randi J Hagerman; Charles E Schwartz; Howard R Slater
Journal:  Hum Mol Genet       Date:  2013-01-10       Impact factor: 6.150

7.  Predictors and risk model development for menopausal age in fragile X premutation carriers.

Authors:  Marian A Spath; Ton B Feuth; Arie P T Smits; Helger G Yntema; Didi D M Braat; Chris M G Thomas; Ad Geurts van Kessel; Stephanie L Sherman; Emily G Allen
Journal:  Genet Med       Date:  2011-07       Impact factor: 8.822

8.  Approaches to identify genetic variants that influence the risk for onset of fragile X-associated primary ovarian insufficiency (FXPOI): a preliminary study.

Authors:  Emily G Allen; Wendy E Grus; Sarayu Narayan; Whitney Espinel; Stephanie L Sherman
Journal:  Front Genet       Date:  2014-08-07       Impact factor: 4.599

Review 9.  Use of model systems to understand the etiology of fragile X-associated primary ovarian insufficiency (FXPOI).

Authors:  Stephanie L Sherman; Eliza C Curnow; Charles A Easley; Peng Jin; Renate K Hukema; Maria Isabel Tejada; Rob Willemsen; Karen Usdin
Journal:  J Neurodev Disord       Date:  2014-08-13       Impact factor: 4.025

10.  Current issues in medically assisted reproduction and genetics in Europe: research, clinical practice, ethics, legal issues and policy. European Society of Human Genetics and European Society of Human Reproduction and Embryology.

Authors:  Joyce C Harper; Joep Geraedts; Pascal Borry; Martina C Cornel; Wybo Dondorp; Luca Gianaroli; Gary Harton; Tanya Milachich; Helena Kääriäinen; Inge Liebaers; Michael Morris; Jorge Sequeiros; Karen Sermon; Françoise Shenfield; Heather Skirton; Sirpa Soini; Claudia Spits; Anna Veiga; Joris Robert Vermeesch; Stéphane Viville; Guido de Wert; Milan Macek
Journal:  Eur J Hum Genet       Date:  2013-11       Impact factor: 4.246

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.